Reviews/Psoriasis Psoriatic Arthritis/Upadacitinib versus adalimumab in biologic-naive psoriatic arthritis
Psa JAK · PSA-JAK-02 · v2
This claim asks whether upadacitinib matches or beats adalimumab on ACR50, a measure of 50% improvement in arthritis symptoms, in patients who have not yet tried biologic drugs. Across every timepoint of a single large trial programme, upadacitinib's ACR50 responses were at least numerically higher than adalimumab's, and at the higher 30 mg dose the difference reached nominal statistical significance [6]. Both doses stayed at least numerically ahead through two [4] and three [5] years of follow-up. The catch is that the trial's formal head-to-head statistical test was set up on the easier ACR20 measure [1], not ACR50, so the ACR50 comparisons were never subjected to the same rigorous testing. The panel judged the direction of the evidence clear and durable, but held back from the top tier because it all comes from one trial and the strongest signal is tied to the higher dose.
All evidence derives from the SELECT-PsA 1 programme in biologic-naive patients. The trial's formal, multiplicity-controlled non-inferiority and superiority tests were pre-specified on ACR20, where both upadacitinib doses were non-inferior to adalimumab and the 30 mg dose was superior [1]. On ACR50, responses were reported as maintained and generally numerically higher than adalimumab through week 56 [3], with greater responses by nominal P value for both doses through week 104 [4], and greater ACR20/50/70 responses at week 152 [5]. The conference report states that more patients achieved ACR50/70 with UPA30 versus adalimumab [6]. The correction restates that ACR50 responses were maintained and numerically higher than adalimumab [7]. The contested point: The division is between direction and statistical rigour: the ACR50 data all point to upadacitinib being at least equal to adalimumab, but no ACR50 comparison was multiplicity-controlled — the formal test was on ACR20 [1]. The explicit superiority statement on ACR50 attaches only to the 30 mg dose [6], while the approved 15 mg dose shows ACR50 only numerically or nominally higher [3][4].
All 8 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Psoriasis Psoriatic Arthritis, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The pre-specified, multiplicity-controlled non-inferiority test was on ACR20 [1], not ACR50. Every ACR50-vs-ADA statement is nominal ('greater by nominal P value' [4]) or descriptive ('numerically higher' [3]), so a formal 'superior' inference on ACR50 is unsupported; only non-inferiority is defensible.
The explicit ACR50 superiority-over-ADA statement attaches to UPA30 [6]; UPA15 (the approved PsA dose) shows ACR50 only numerically/nominally higher [3][4]. The dose-agnostic claim leans on the higher, less clinically representative dose for its strongest support.
Where it remains uncertain. The pre-specified non-inferiority/superiority test was on ACR20, not ACR50 [1], so every ACR50-vs-adalimumab statement is nominal or descriptive, and the clearest superiority signal is confined to the 30 mg dose [6].
Aleatory
ACR50 response proportions carry sampling noise, and small numerical gaps versus adalimumab that are not multiplicity-controlled could arise by chance.
The load-bearing papers from a corpus of 8, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Establishes the non-inferiority/superiority-vs-ADA framework, but on ACR20 — the ACR50 claim is an extrapolation from this design.
“Both upadacitinib doses were noninferior to adalimumab for the ACR20 response at week 12; the 30-mg dose but not the 15-mg dose was superior to adalimumab.”
Panel auditInternal validity: high · scope of inference: Biologic-naive (non-biologic DMARD-IR) active PsA patients, ACR20 response at week 12 versus adalimumab.Key limitations: ACR50 not reported in abstract · week 12 only · no participant counts given
Shows ACR50 at least non-inferior (numerically higher) through 56 weeks for upadacitinib overall.
“ACR20/50/70, PASI75/90/100 and MDA responses were maintained with upadacitinib through week 56 and were generally numerically higher than with adalimumab”
Panel auditInternal validity: high · scope of inference: Biologic-naive active PsA patients, durability of ACR50 and other responses versus adalimumab through week 56.Key limitations: no statistics for ACR50 · 'generally numerically higher' is qualitative · no ACR50 point estimates or N
Extends ACR50 superiority signal to both doses (nominal) at 2 years.
“greater responses by nominal P value were observed with UPA15 and UPA30 versus ADA for ACR20/50/70 and MDA”
Panel auditInternal validity: high · scope of inference: Biologic-naive active PsA patients, ACR50 and other responses versus adalimumab through 2 years.Key limitations: nominal P values only · ACR50 bundled with ACR20/70 · no ACR50-specific point estimates or N
3 of 8 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Falls short of Established because ACR50 was not a formally non-inferiority-tested endpoint (ACR20 was [1]), all evidence is a single trial programme, and the clearest superiority signal is dose-restricted to UPA30.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No multiplicity-controlled ACR50 test. The formal non-inferiority/superiority hierarchy was on ACR20 [1], so no controlled inference exists for ACR50 versus adalimumab. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A trial with ACR50 pre-specified in the testing hierarchy against adalimumab, powered for that endpoint.
Open question: Would upadacitinib demonstrate formally tested ACR50 non-inferiority or superiority to adalimumab if ACR50 were placed in the multiplicity-controlled hierarchy? Why it is still open: The pre-specified test was on ACR20 [1]; all ACR50 comparisons are nominal [4] or descriptive [3].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19